193 related articles for article (PubMed ID: 36879495)
21. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia.
Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC
Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671
[TBL] [Abstract][Full Text] [Related]
23. Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study.
Herrmann L; Kimmig A; Rödel J; Hagel S; Rose N; Pletz MW; Bahrs C
Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34199546
[TBL] [Abstract][Full Text] [Related]
24. [Antimicrobial resistance monitoring of gram-negative bacilli isolated from 15 teaching hospitals in 2014 in China].
Wang Q; Wang H; Yu Y; Xu X; Sun Z; Lu J; Yang B; Zhang L; Hu Z; Feng X; Xu Y; Ni Y; Mei Y; Liao K; Ji P; Chu Y
Zhonghua Nei Ke Za Zhi; 2015 Oct; 54(10):837-45. PubMed ID: 26675021
[TBL] [Abstract][Full Text] [Related]
25. Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales.
Ávila-Núñez M; Lima O; Sousa A; Represa M; Rubiñán P; Celestino P; Garrido-Ventín M; García-Formoso L; Vasallo-Vidal F; Martinez-Lamas L; Pérez-Landeiro A; Rubianes M; Pérez-Rodríguez MT
Ann Clin Microbiol Antimicrob; 2023 Aug; 22(1):75. PubMed ID: 37592268
[TBL] [Abstract][Full Text] [Related]
26. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Kays MB
Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
[TBL] [Abstract][Full Text] [Related]
27. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
Hilty M; Sendi P; Seiffert SN; Droz S; Perreten V; Hujer AM; Bonomo RA; Mühlemann K; Endimiani A
Int J Antimicrob Agents; 2013 Mar; 41(3):236-49. PubMed ID: 23313399
[TBL] [Abstract][Full Text] [Related]
28. Antibiotic Resistances of Enterobacteriaceae with Chromosomal Ampc in Urine Cultures: Review and Experience of a Spanish Hospital.
Rodríguez-Guerrero E; Cabello HR; Expósito-Ruiz M; Navarro-Marí JM; Gutiérrez-Fernández J
Antibiotics (Basel); 2023 Apr; 12(4):. PubMed ID: 37107092
[TBL] [Abstract][Full Text] [Related]
29. Effect of ampC derepression on cefepime MIC in Enterobacterales with chromosomally encoded inducible AmpC β-lactamase.
Kohlmann R; Bähr T; Gatermann SG
Clin Microbiol Infect; 2019 Sep; 25(9):1158.e1-1158.e4. PubMed ID: 31128286
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Phoenix Automated Microbiology System for detecting extended-spectrum beta-lactamases among chromosomal AmpC-producing Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, and Serratia marcescens.
Park YJ; Yu JK; Lee S; Park JJ; Oh EJ
Ann Clin Lab Sci; 2007; 37(1):75-8. PubMed ID: 17311873
[TBL] [Abstract][Full Text] [Related]
31. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
32. Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysis.
Dequidt T; Bastian S; Nacher M; Breurec S; Carles M; Thiery G; Camous L; Tressieres B; Valette M; Pommier JD
Crit Care; 2023 Nov; 27(1):418. PubMed ID: 37915017
[TBL] [Abstract][Full Text] [Related]
33. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
34. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
[TBL] [Abstract][Full Text] [Related]
35. Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.
Xie L; Xu R; Zhu D; Sun J
Infect Genet Evol; 2022 Aug; 102():105301. PubMed ID: 35568334
[TBL] [Abstract][Full Text] [Related]
36. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases.
Mushtaq S; Ge Y; Livermore DM
Antimicrob Agents Chemother; 2004 Apr; 48(4):1313-9. PubMed ID: 15047535
[TBL] [Abstract][Full Text] [Related]
37. Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS; Belley A; Barth P; Lahlou O; Knechtle P; Motta P; Velicitat P
JAMA; 2022 Oct; 328(13):1304-1314. PubMed ID: 36194218
[TBL] [Abstract][Full Text] [Related]
38. Selection of hyperproduction of AmpC and SME-1 in a carbapenem-resistant Serratia marcescens isolate during antibiotic therapy.
Hemarajata P; Amick T; Yang S; Gregson A; Holzmeyer C; Bush K; Humphries RM
J Antimicrob Chemother; 2018 May; 73(5):1256-1262. PubMed ID: 29471486
[TBL] [Abstract][Full Text] [Related]
39. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
40. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
